Search
NOP-1A
go.drugbank.com/drugs/DB15208InvestigationalNOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).
Synonyms: NOP-1AN-acetylsulfanilyl chloride
go.drugbank.com/drugs/DB12337InvestigationalASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.
Lucanthone
go.drugbank.com/drugs/DB04967InvestigationalIt is currently being tested as a radiation sensitizer. … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).
UDP-alpha-D-glucuronic acid
go.drugbank.com/drugs/DB03041ExperimentalIt may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones. … A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis.
Picoplatin
go.drugbank.com/drugs/DB04874InvestigationalPicoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors. … It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.
CERE-110
go.drugbank.com/drugs/DB05898InvestigationalCERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. … This drug is developed by Ceregene and currently under phase I of clinical trial.
Nitroaspirin
go.drugbank.com/drugs/DB12445InvestigationalNitroaspirin has been investigated for the treatment of Intermittent Claudication.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSIR502
go.drugbank.com/drugs/DB06463ExperimentalIR502 (Zorcell) is a potential treatment for psoriasis.
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781Investigationalfor the treatment of advanced non-small cell lung cancer (NSCLC). … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated